anti-EGFR targeted therapy
Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer
... of EGFR signaling pathways; however, like HCC-1937, it carries homozygous deleterious mutations in BRCA1 ...to anti-EGFR ...of EGFR, and combined treatments synergistically reduced levels of ...
21
Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy.
... 3.1. Receptor Tyrosine Kinase Inhibitor Combinations In theory, combination of RTKIs is considered as an attractive option because it can prevent primary and secondary therapeutic resistance. The first strategy, called ...
17
Preferential Response of Basal-Like Head and Neck Squamous Cell Carcinoma Cell Lines to EGFR-Targeted Therapy Depending on EREG-Driven Oncogenic Addiction
... the EGFR pathway, indicating sensitivity to inhibition of EGFR [ 9 , 10 ...the anti-EGFR monoclonal antibody ...where anti-EGFR TKIs have yielded disappointing ...
18
Constitutive or Induced HIF-2 Addiction is Involved in Resistance to Anti-EGFR Treatment and Radiation Therapy in HNSCC
... include anti-Epidermal Growth Factor Receptor (EGFR) antibodies and radiotherapy, but resistance emerges in most ...to EGFR blockade in metastatic colorectal cancer but are infrequent in HNSCC, ...
17
Combined irradiation and targeted therapy or immune checkpoint blockade in brain metastases: toxicities and efficacy
... Among six retrospective trials assessing the concomitant use of TKIs and WBRT for NSCLC patients with BM [ 28 , 31 , 34 – 36 , 41 ] only one small retrospective study, including eight patients, re- ported unexpected ...
16
Specific Targeting of Caspase-9/PP2A Interaction as Potential New Anti-Cancer Therapy
... have targeted protein-protein interactions involved in anti-apoptotic signalling, including (i) the peptide shepherdin mimicking a small domain of the survivin protein that interacts with Hsp90 [34] (ii) ...
13
Anti-HER2 vaccines: new prospects for breast cancer therapy.
... another anti- HER2 peptide-based vaccine which was administered in combination with trastuzumab ...combination therapy with trastuzumab and anti-HER2 vaccines has an immunological benefit; on the ...
44
Ultrasmall AGuIX theranostic nanoparticles for vascular-targeted interstitial photodynamic therapy of glioblastoma
... Conclusion In this study, we designed a new AGuIX NP for MRI-guided VTP of GBM. It combines MRI contrast agents, a PS for the photodynamic effect and a new peptide targeting NRP-1 receptor overexpressed by the tumor ...
15
EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy.
... characterized EGFR ligands, where ligand binding promotes receptor homodimerization and subsequent phosphorylation of the intracytoplasmic kinase domain 16 ...of EGFR-specific reagents in the target cells ...
32
Sexual Dimorphisms, Anti-Hormonal Therapy and Cardiac Arrhythmias
... Turner syndrome (TS) is a well-known cause of POI and is associated with a risk of heart disease [ 56 ]. TS is a classic situation with low progesterone and estradiol levels and a high FSH level, which could therefore ...
20
Fischer 344 Rat: A Preclinical Model for Epithelial Ovarian Cancer Folate-Targeted Therapy
... recently confirmed the expression of FRα by the organs of the female genital tractus [15] . They have observed that ovaries do not express the receptor under normal conditions, but that the salpinx epithelium does. ...
13
Combined targeting of EGFR/HER promotes anti-tumor efficacy in subsets of KRAS mutant lung cancer resistant to single EGFR blockade.
... two EGFR mutant cell lines ...and EGFR reveals partial homologies, ...of EGFR beginning at position 2098 (data not shown). In H1650 mutant EGFR cells, mutant KRAS knockdown also reduced KRAS ...
13
Synthesis of lutetium-carrying oligonucleotides for targeted cancer therapy and imaging
... In cancer therapy there is need for targeted treatment that kills tumour cells selectively while minimizing damage to healthy cells. In this regard, specific targeting of tumours through ...
1
Development of aptamer-based radiopharmaceuticals for targeted cancer imaging and therapy
... SCK•CEN Academy II Boeretang 200 II BE-2400 Mol II http://academy.sckcen.be II academy@sckcen.be II Posternr: Development of aptamer-based radiopharmaceuticals for targeted cancer imaging and therapy M. ...
1
Impact of Mouse Model on Pre-Clinical Dosimetry in Targeted Radionuclide Therapy
... Abstract Introduction: Small animal dosimetry serves as an important link in establishing a relationship between absorbed dose and biological effect during pre-clinical targeted radionuclide therapy. ...
28
EGFR, régénération et carcinogenèse hépatiques : quelle responsabilité ?
... tumeurs. EGFR : epider- mal growth factor receptor ; HGF : hepatocyte growth factor ; HGFR : récepteur de l’HGF : TGF : transforming growth factor beta ; TGF R : récepteur du TGF ; uPA : urokinase-type ...
4
Correction of human phospholamban R14del mutation associated with cardiomyopathy using targeted nucleases and combination therapy
... 44 targeted a frame shift mutations in myosin- binding protein C3 (Mybpc3), encoding cardiac MyBP-C (cMyBP-C) associated with ...gene therapy approach with knockdown of the endogenous mutant gene along with ...
11
Anti-RANKL therapy for bone tumours: Basic, pre-clinical and clinical evidences
... demonstrated that denosumab significantly delayed the time of first SRE (Skeletal Related Event) but also the risk of multiple SRE and whether zoledronic acid showed similar effects, statistical analyses are in favour ...
39
en fr Targeted therapy against OX40 ligand in murine models of systemic sclerosis Thérapie ciblée anti-OX40 Ligand dans des modèles murins de Sclérodermie systémique
... auto-anticorps anti-topoisomérases de type 1 ont été ...neutralisant anti-TGF-β ou par anticorps activant les intégrines α-1 a induit la régression des lésions de fibrose et des anomalies ...
335
en fr Development of a new anti-cancer agent for targeted radionuclide therapy : ß- radiolabeled RAFT-RGD. Le RAFT-RGD radiomarqué avec un émetteur °- comme nouvel agent de radiothérapie interne vectorisée
... Lu-RAFT-RGD. 8. Efficacité du traitement au 90 Y-RAFT-RGD Les tumeurs poussent de manière hétérogène sur les souris d’une même série, ce qui nous amène à travailler avec des groupes de souris aux volumes tumoraux très ...
223